Brighter's main patent has been approved by United States Patent and Trademark Office.
The United States Patent and Trademark Office (USPTO) has granted Brighter's main patent in the United States, which includes Actiste and its unique ability to integrate all functions in a patient's activity chain into one and the same device, i.e. measuring and analyzing a biomarker (e.g. blood glucose), and injecting medicine (e.g. insulin).
“The approval of our main patent means that an important piece in our global expansion plan is now in place. The potential in the United States is enormous given the large number of people living with diabetes there and across the entire American continent. And although we chose to initially launch the solution in Sweden, Indonesia and Thailand, the US, as well as major parts of Latin America, are important markets that we expect to expand into in the future," says Truls Sjöstedt, Brighter's CEO and founder.
The grant concerns Brighter's main patent, which protects the company's unique integration of all functionalities, i.e. measuring and analyzing a biomarker and injecting medicine into one and the same instrument. Actiste is the company's first application based on this, which means a mobile-connected and fully integrated tool for diabetic blood sampling, blood sugar analysis and insulin injection. The US Patent Office's decision implies that the Company has all rights to the patent and its associated patent family.
In order to be able to sell Actiste on the US market, an approval of the Federal Drug Administration (FDA) is required. In the development of Actiste, Brighter has taken into account American standards and partly developed its ISO 13485 quality system for the development and production of medical devices to ensure that it also complies with FDA processes and standards. This means that Brighter can apply for FDA approval and/or clearance without further investment in adapting the design of Actiste, in systems and document management.
Brighter's patent strategy is based on the main patent and where the company's ongoing research and development, resulting in new patents, complements and strengthens the company's intellectual property protection, which in turn extends the life of existing patents.
According to the International Diabetes Federation today, about 10.8 percent of the United States population is suffering from diabetes, which corresponds to approximately 29 million people. This means that the country has the most diabetic in the world, after China and India. In addition to the 29 million people already living with diabetes in the country, it is estimated that there are about 86 million Americans who are in a precursor to the disease, which leads to an increased risk of suffering from diabetes and other chronic diseases. The US market is considered to be the largest and most profitable market for medical devices.
For more information, please contact:
Truls Sjöstedt, CEO
Tel: +46 709 73 46 00
Email: truls.sjostedt@brighter.se
Henrik Norström, COO
Tel: +46 733 40 30 45
Email: henrik.norstrom@brighter.se
About Brighter AB (publ)
Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.
The Company's shares are listed on NASDAQOMX First North/BRIG . Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com , www.remium.com .
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 10:30 CET on August 22, 2017.
Tags: